Predicting the clinical behavior of ovarian cancer from gene expression profiles.
We investigated whether prognostic information is reflected in the expression patterns of ovarian carcinoma samples. RNA obtained from seven FIGO stage I without recurrence, seven platin-sensitive advanced-stage (III or IV), and six platin-resistant advanced-stage ovarian tumors was hybridized on a complementary DNA microarray with 21,372 spotted clones. The results revealed that a considerable number of genes exhibit nonaccidental differential expression between the different tumor classes. Principal component analysis reflected the differences between the three tumor classes and their order of transition. Using a leave-one-out approach together with least squares support vector machines, we obtained an estimated classification test accuracy of 100% for the distinction between stage I and advanced-stage disease and 76.92% for the distinction between platin-resistant versus platin-sensitive disease in FIGO stage III/IV. These results indicate that gene expression patterns could be useful in clinical management of ovarian cancer.
De Smet
F
F
Department of Electrical Engineering ESAT-SCD, K.U.Leuven, Leuven-Heverlee, Belgium.
Pochet
N L M M
NL
Engelen
K
K
Van Gorp
T
T
Van Hummelen
P
P
Marchal
K
K
Amant
F
F
Timmerman
D
D
De Moor
B L R
BL
Vergote
I B
IB
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D017671:Platinum Compounds / Q000627:therapeutic use; D011237:Predictive Value of Tests
D000970:Antineoplastic Agents; D017671:Platinum Compounds